PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.
Last trade$9.76
Day change+$0.22 (+2.31%)
Day range$9.50 – $9.96
Volume610,755
Market cap$542M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$542.39M
Price / earnings
34.39×
Price / book
9.02×
Price / sales
5.39×
EV / sales
5.17×
EV / EBITDA
19.64×
Profitability
Earnings per share
$0.28
Return on assets
4.98%
Return on equity
26.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.09×
Current ratio
1.14×
Quick ratio
1.14×
Cash ratio
0.11×
Cash flow
Price / cash flow
7.24×
Price / free cash flow
7.38×
Free cash flow
$73.51M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PAYS, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$28.25M
$28.04M
$22.76M
$21.6M
$19.08M
$18.6M
$15.61M
$15.26M
Cost of revenue
$10.36M
$9.82M
$9.63M
$9.45M
$7.32M
$6.91M
$6.41M
$6.78M
Gross profit
$17.9M
$18.22M
$13.12M
$12.15M
$11.76M
$11.69M
$9.2M
$8.47M
Selling, general and administrative
$8.55M
$8.91M
$9.06M
$8.38M
$8.2M
$7.4M
$7.03M
$6.22M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$10.89M
$11.55M
$11.27M
$10.57M
$10.32M
$9.2M
$8.73M
$7.78M
Operating income
$7.01M
$6.67M
$1.85M
$1.58M
$1.44M
$2.49M
$464.33K
$689.85K
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$7.91M
$7.47M
$2.49M
$2.25M
$2.04M
$3.25M
$1.24M
$1.49M
Income taxes
$1.15M
$2.03M
$1.13M
$30.48K
$655.01K
$665.16K
-$137.27K
$53.73K
Net income
$6.76M
$5.44M
$1.36M
$2.22M
$1.39M
$2.59M
$1.37M
$1.44M
Net income attributable to common shareholders
$6.76M
$5.44M
$1.36M
$2.22M
$1.39M
$2.59M
$1.37M
$1.44M
EBITDA
$9.35M
$9.3M
$4.06M
$3.77M
$3.56M
$4.29M
$2.17M
$2.26M
Basic earnings per share
$0.12
$0.10
$0.02
$0.04
$0.03
$0.05
$0.02
$0.03
Diluted earnings per share
$0.11
$0.09
$0.02
$0.04
$0.02
$0.05
$0.02
$0.03
Recent news
Company coverage with links to the original publishers.
Paysign reported 43% year-over-year revenue growth to $30.8 million in Q3 2026, driven by its pharmaceutical patient affordability business which grew 110% to $16.6 million. The company is shifting from lower-margin plasma donor card processing toward higher-margin patient assistance solutions. While a plasma client transition will reduce Q4 revenue by $1.5 million, management expects to offset losses through client expansion. With $34.5 million in cash and zero debt, Paysign is positioned to scale its software platform across new medical verticals.
Zacks recommends Paysign (PAYS) as a top growth stock, citing its exceptional earnings growth of 376.9% expected this year, strong cash flow growth of 61.8%, and positive earnings estimate revisions. The company holds a Growth Score of B and Zacks Rank #2 (Buy), positioning it well for potential outperformance among growth investors.
Paysign, Inc. (PAYS) has been upgraded to Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The company is expected to earn $0.62 per share for fiscal year 2026, with analysts raising consensus estimates by 6.9% over the past three months. The upgrade positions Paysign in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation driven by improving business fundamentals.
Paysign stock dropped 12.3% despite beating Q1 earnings expectations with 50.8% revenue growth and 80% EPS growth. The decline was triggered by management's decision to maintain prior guidance rather than raise it, disappointing investors after the stock had already rallied 35% year-to-date. At 23.5x forward earnings with nearly 100% projected earnings growth, analysts suggest the stock may be attractive at current levels, though small-cap risks remain.
Paysign (NASDAQ: PAYS) reported strong Q1 2026 results with 51% revenue growth to $28.04 million, driven by 82% pharma revenue growth and 25% plasma revenue growth. Net income nearly doubled to $5.44 million ($0.09 per share), with adjusted EBITDA up 113% to $10.59 million. The company added 45 net patient affordability programs (135 total) and 89 plasma centers (573 total), exceeding guidance across all metrics.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.